Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,199,819
  • Shares Outstanding, K 92,738
  • Annual Sales, $ 4,010 K
  • Annual Income, $ -214,530 K
  • EBIT $ -278 M
  • EBITDA $ -283 M
  • 60-Month Beta 0.62
  • Price/Sales 1,274.95
  • Price/Cash Flow N/A
  • Price/Book 5.30

Options Overview Details

View History
  • Implied Volatility 43.83% ( +4.96%)
  • Historical Volatility 40.96%
  • IV Percentile 2%
  • IV Rank 18.01%
  • IV High 88.58% on 03/15/24
  • IV Low 34.00% on 09/24/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 16
  • Volume Avg (30-Day) 96
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 2,276
  • Open Int (30-Day) 2,967

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.94
  • Number of Estimates 8
  • High Estimate -0.80
  • Low Estimate -1.15
  • Prior Year -0.90
  • Growth Rate Est. (year over year) -4.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.85 +7.62%
on 11/18/24
62.53 -9.05%
on 11/14/24
-1.83 (-3.12%)
since 10/21/24
3-Month
49.13 +15.77%
on 09/24/24
62.53 -9.05%
on 11/14/24
+2.91 (+5.39%)
since 08/21/24
52-Week
29.72 +91.35%
on 11/22/23
62.53 -9.05%
on 11/14/24
+26.93 (+89.95%)
since 11/21/23

Most Recent Stories

More News
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

CRNX : 57.09 (+1.82%)
Crinetics Pharmaceuticals to Showcase Novel Nonpeptide Drug Conjugate Platform and Phase 2 Data for Paltusotine at NANETS 2024

Crinetics Pharmaceuticals will present preclinical data on CRN09682 and Paltusotine at NANETS 2024.Quiver AI SummaryCrinetics Pharmaceuticals, Inc. announced the debut of its innovative nonpeptide drug...

CRNX : 57.09 (+1.82%)
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

CRNX : 57.09 (+1.82%)
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

CRNX : 57.09 (+1.82%)
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

CRNX : 57.09 (+1.82%)
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 57.09 (+1.82%)
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024

CRNX : 57.09 (+1.82%)
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 57.09 (+1.82%)
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

CRNX : 57.09 (+1.82%)
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

CRNX : 57.09 (+1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly,...

See More

Key Turning Points

3rd Resistance Point 58.58
2nd Resistance Point 57.50
1st Resistance Point 56.79
Last Price 57.09
1st Support Level 55.00
2nd Support Level 53.92
3rd Support Level 53.21

See More

52-Week High 62.53
Last Price 57.09
Fibonacci 61.8% 50.00
Fibonacci 50% 46.13
Fibonacci 38.2% 42.25
52-Week Low 29.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar